Italy respiratory device market was valued at around $639 million in 2018 and is estimated to grow at a CAGR of around 5.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors that augmenting the growth of respiratory device market in the country. Further, well-developed healthcare infrastructure and the presence of key market players in the country are fueling the growth of the country’s market. Market players operating in the country are adopting various strategies which are providing the needful thrust to the market growth.
Get Free Sample link @ https://www.omrglobal.com/request-sample/italy-respiratory-device-market
Italy respiratory device market is segmented on the basis of product and end-user. The respiratory product segment is further sub-segmented into therapeutic devices, diagnosis and monitoring devices, and consumables and accessories. The therapeutic devices segment is estimated to dominate the market and is also anticipated to grow at the fastest growth rate over the forecast period. The high cost of therapeutics device and significant demand for continuous positive airway pressure (CPAP) devices and masks, ventilator, oxygen concentrator, and oxygen hoods contribute majorly to the segmental growth of the market for therapeutic devices. Based on end-user, the market is analyzed into hospitals and clinics, and home care.
Additionally, the market is characterized by the presence of several players that are providing respiratory devices within and outside the region. Some of the key players of the market include Bayer AG, ResMed Corp., Chiesi Farmaceutici S.P.A., GlaxoSmithKline PLC, Novartis AG, Boehringer Ingelheim International GmbH, and others. These players are adopting various strategies in order to capitalize on market growth opportunities. Mergers and acquisitions, product launch, partnerships and collaborations, and geographical expansion are some of the majorly adopted strategies by the market players. For instance, in September 2017, Chiesi Farmaceutici S.P.A completed the clinical study of Tribute with its Trimbow an extra-fine fixed-dose triple combination inhaler. Upon successful commercialization of this inhaler in the country in the near future, the market for inhalers will grow.
A full report of Italy Respiratory Device Market available @ https://www.omrglobal.com/industry-reports/italy-respiratory-device-market
Italy Respiratory Device Market Segmentation
By Product
- Therapeutic Devices
- Diagnostic and Monitoring Devices
- Consumable and Accessories
By End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- Air Liquide S.A.
- AstraZeneca PLC
- Bayer AG
- Bespak
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici S.P.A.
- Gilbert Technologies B.V.
- GlaxoSmithKline PLC
- H&T Presspart Manufacturing Ltd.
- Hamilton Medical AG
- Koninklijke Philips N.V.
- Medtronic PLC
- Novartis AG
- PMD Device Solutions Ltd.
- ResMed Corp.
- Savara, Inc.
- Teicos Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
